Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

11.71

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

-0.03

EPS Last/This Y

0.38

EPS This/Next Y

0.03

Price

1.51

Target Price

7.56

Analyst Recom

1.64

Performance Q

31.3

Relative Volume

0.83

Beta

0.51

Ticker: ALLO




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13ALLO1.1950.740.216901
2025-11-14ALLO1.240.733.506951
2025-11-17ALLO1.2350.730.306958
2025-11-18ALLO1.3050.750.066890
2025-11-19ALLO1.270.75999.996864
2025-11-20ALLO1.2350.760.016814
2025-11-21ALLO1.2250.790.026653
2025-11-24ALLO1.3450.180.042427
2025-11-25ALLO1.360.160.002875
2025-11-26ALLO1.410.140.003141
2025-12-01ALLO1.370.130.003428
2025-12-02ALLO1.3450.138.003496
2025-12-03ALLO1.5150.130.033505
2025-12-04ALLO1.4450.130.033498
2025-12-05ALLO1.4250.130.013515
2025-12-08ALLO1.4450.130.003544
2025-12-09ALLO1.420.130.473600
2025-12-10ALLO1.480.120.503530
2025-12-11ALLO1.5450.120.213636
2025-12-12ALLO1.510.120.003666
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13ALLO1.2012.0- -0.97
2025-11-14ALLO1.2417.0- -0.97
2025-11-17ALLO1.2417.0- -0.97
2025-11-18ALLO1.3017.0- -0.96
2025-11-19ALLO1.2617.0- -0.96
2025-11-20ALLO1.2417.0- -0.96
2025-11-21ALLO1.2318.2- -0.96
2025-11-24ALLO1.3518.2- -0.96
2025-11-25ALLO1.3618.2- -0.96
2025-11-26ALLO1.4118.2- -0.96
2025-12-01ALLO1.3720.3- -0.94
2025-12-02ALLO1.3420.3- -0.94
2025-12-03ALLO1.5220.3- -0.94
2025-12-04ALLO1.4520.3- -0.94
2025-12-05ALLO1.4320.3- -0.94
2025-12-08ALLO1.4520.3- -0.94
2025-12-09ALLO1.4220.3- -0.94
2025-12-10ALLO1.4920.3- -0.94
2025-12-11ALLO1.5520.3- -0.94
2025-12-12ALLO1.5120.3- -0.94
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13ALLO-0.11-5.2912.26
2025-11-14ALLO-0.11-5.2912.29
2025-11-17ALLO-0.11-2.7012.29
2025-11-18ALLO-0.11-2.7012.20
2025-11-19ALLO-0.11-2.7012.20
2025-11-20ALLO-0.11-2.7012.20
2025-11-21ALLO-0.11-2.7011.98
2025-11-24ALLO-0.11-9.5711.98
2025-11-25ALLO-0.11-9.5711.98
2025-11-26ALLO-0.11-9.5711.73
2025-12-01ALLO-0.11-9.5611.73
2025-12-02ALLO-0.11-9.5611.73
2025-12-03ALLO-0.11-9.5611.73
2025-12-04ALLO-0.11-9.5611.73
2025-12-05ALLO-0.11-9.5611.73
2025-12-08ALLO-0.11-9.5611.73
2025-12-09ALLO-0.11-9.5611.73
2025-12-10ALLO-0.11-9.5611.71
2025-12-11ALLO-0.11-9.5611.71
2025-12-12ALLO-0.11-9.5611.71
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="ALLO" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.19

Avg. EPS Est. Current Quarter

-0.22

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

-0.11

Institutional Transactions

-9.56

Beta

0.51

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

9

Growth Score

22

Sentiment Score

54

Actual DrawDown %

96.1

Max Drawdown 5-Year %

-97.6

Target Price

7.56

P/E

Forward P/E

PEG

P/S

P/B

1.07

P/Free Cash Flow

EPS

-0.98

Average EPS Est. Cur. Y​

-0.94

EPS Next Y. (Est.)

-0.91

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.83

Return on Equity vs Sector %

-94.1

Return on Equity vs Industry %

-79.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.09

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”ALLO” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ALLO” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ALLO” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ALLO” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ALLO” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ALLO” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ALLO” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Allogene Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading